Current Therapy of Drugs in Amyotrophic Lateral Sclerosis

Author(s): Haiyan Lu, Wei Dong Le, Ya-Ying Xie, Xiao-Ping Wang

Journal Name: Current Neuropharmacology

Volume 14 , Issue 4 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Amyotrophic lateral sclerosis (ALS), commonly termed as motor neuron disease (MND) in UK, is a chronically lethal disorder among the neurodegenerative diseases, meanwhile. ALS is basically irreversible and progressive deterioration of upper and lower motor neurons in the motor cortex, brain stem and medulla spinalis. Riluzole, used for the treatment of ALS, was demonstrated to slightly delay the initiation of respiratory dysfunction and extend the median survival of patients by a few months. In this study, the key biochemical defects were discussed, such as: mutant Cu/Zn superoxide dismutase, mitochondrial protectants, and anti-excitotoxic/ anti-oxidative / antiinflammatory/ anti-apoptotic agents, so the related drug candidates that have been studied in ALS models would possibly be further used in ALS patients.

Keywords: Amyotrophic lateral sclerosis, motor neuron disease, neurodegenerative disease, SOD1 mutations, riluzole, edaravone, pyrimethamine.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 20 January, 2016
Page: [314 - 321]
Pages: 8
DOI: 10.2174/1570159X14666160120152423

Article Metrics

PDF: 106
HTML: 13
PRC: 1